Patents by Inventor CHARLES DUMONTET
CHARLES DUMONTET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210177755Abstract: The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.Type: ApplicationFiled: October 30, 2018Publication date: June 17, 2021Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Léon BérardInventors: Charles DUMONTET, Abdelkamel CHETTAB
-
Patent number: 9896415Abstract: The present invention relates to the compounds of formula (I): wherein: R2, R4 and R6, either identical or different, represent a hydrogen, chlorine bromine, iodine or fluorine atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; R2? and R4?, either identical or different, represent a hydrogen atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; with R2? and/or R4? which represent a methoxy group; n is equal to 1, 2, 3; X?CH2, O, S or N(R7); and R7 represents a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms; as well as pharmaceutically acceptable hydrates, solvates and salts thereof.Type: GrantFiled: April 4, 2014Date of Patent: February 20, 2018Assignees: UNIVERSITE CLAUDE BERNARD LYON I, HOSPICES CIVILS DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Charles Dumontet, Ahcene Boumendjel, Guillaume Monneret
-
Patent number: 9783541Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.Type: GrantFiled: September 29, 2014Date of Patent: October 10, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, HOSPICES CIVILS DE LYON, ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE DE MONTPELLIER 1Inventors: Laurent Chaloin, Suzanne Peyrottes, Corinne Lionne, Zsuzsanna Marton, David Egron, Remi Guillon, Christian Perigaud, Charles Dumontet, Lars Petter Jordheim, Isabelle Krimm
-
Publication number: 20170114146Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: September 30, 2016Publication date: April 27, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Tanja Fauti, Charles Dumontet, Pablo Umana, Marina Bacac, Anne Freimoser-Grundschober
-
Publication number: 20160272643Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.Type: ApplicationFiled: September 29, 2014Publication date: September 22, 2016Inventors: Laurent Chaloin, Suzanne Peyrottes, Corinne Lionne, Zsuzsanna Marton, David Egron, Remi Guillon, Christian Perigaud, Charles Dumontet, Lars Petter Jordheim, Isabelle Krimm
-
Publication number: 20160052881Abstract: The present invention relates to the compounds of formula (I): wherein: R2, R4 and R6, either identical or different, represent a hydrogen, chlorine bromine, iodine or fluorine atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; R2? and R4?, either identical or different, represent a hydrogen atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; with R2? and/or R4? which represent a methoxy group; n is equal to 1, 2, 3; X?CH2, O, S or N(R7); and R7 represents a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms; as well as pharmaceutically acceptable hydrates, solvates and salts thereof.Type: ApplicationFiled: April 4, 2014Publication date: February 25, 2016Inventors: Charles DUMONTET, Ahcene BOUMENDJEL, Guillaume MONNERET
-
Publication number: 20160000911Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.Type: ApplicationFiled: June 5, 2014Publication date: January 7, 2016Applicant: ROCHE GLYCART AGInventors: CHARLES DUMONTET, THOMAS FRIESS, FRANK HERTING, CHRISTIAN KLEIN, PABLO UMANA
-
Publication number: 20140363500Abstract: The current invention is directed to particulate or vesicular immunomodulators, like e.g. cytokines, for use in combination therapy with antibodies for treatments of a range of conditions and diseases, in particular cancer, as well as methods, compositions, and kits thereof.Type: ApplicationFiled: August 27, 2014Publication date: December 11, 2014Inventors: Charles DUMONTET, Esben A. NILSSEN
-
Publication number: 20140065134Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.Type: ApplicationFiled: March 14, 2013Publication date: March 6, 2014Applicant: ROCHE GLYCART AGInventors: CHARLES DUMONTET, THOMAS FRIESS, FRANK HERTING, CHRISTIAN KLEIN, PABLO UMANA
-
Publication number: 20140038883Abstract: The present invention relates to compounds of formula (I), where R1 and R2, identical or different, are each independently a hydrogen atom or a non-substituted or substituted (C1-C12) alkyl group; R3 is a hydrogen atom or a non-substituted or substituted (C1-C6) alkyl group; R4 is a non-substituted or substituted (C1-C12) alkyl group or an aryl or heteroaryl group, said aryl and heteroaryl groups being non-substituted or substituted; and R5 is a non-substituted or substituted (C1-C12) alkyl group; or R4 and R5 are bonded to one another by a saturated hydrocarbon chain having 3 or 4 carbon atoms, optionally in hydrated form or in the form of a salt that is acceptable for being administered to animals or plants, for the use thereof as a potentiator of the effect of an antimicrobial agent or for the use thereof as an antimicrobial agent.Type: ApplicationFiled: January 27, 2012Publication date: February 6, 2014Applicants: UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE JOSEPH FOURIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, HOSPICES CIVIL DE LYONInventors: Anne Doleans-Jordheim, Jean Freney, Charles Dumontet, Ahcene Boumend Jel, Jean-Baptiste Veron, Yung-Sing Wong
-
Publication number: 20120301459Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.Type: ApplicationFiled: October 28, 2011Publication date: November 29, 2012Applicant: Hoffman-La Roche. Inc.Inventors: Charles Dumontet, Thomas Friess, Frank Herting, Christian Klein, Pablo Umana
-
Publication number: 20120045523Abstract: The present invention relates to a drug comprising separately or together (i) a TLR3 ligand and (ii) a chemotherapeutic agent that acts on the intrinsic apoptotic pathway, for simultaneous or sequential administration in the treatment of cancer, wherein the chemotherapeutic agent is selected from topoisomerase II inhibitors, platinum-derived alkylating agents and PI3 kinase inhibitors.Type: ApplicationFiled: July 31, 2009Publication date: February 23, 2012Applicants: UNIVERSITE CLAUDE BERNARD LYON I, HOSPICES CIVILS DE LYONInventors: Serge Lebecque, Charles Dumontet, Yves Pacheco, Claire Rodriguez-Lafrasse, Florent Toscano, Yann Estornes, Francois Virard, Isabelle Coste-Invernizzi, Toufic Renno
-
Publication number: 20110177067Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.Type: ApplicationFiled: March 7, 2011Publication date: July 21, 2011Applicant: Hoffman-La Roche, Inc.Inventors: Charles Dumontet, Thomas Friess, Frank Herting, Christian Klein, Pablo Umana
-
Publication number: 20100310581Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.Type: ApplicationFiled: May 10, 2010Publication date: December 9, 2010Applicant: Hoffman-La Roche. Inc.Inventors: Charles Dumontet, Thomas Friess, Frank Herting, Christian Klein, Pablo Umana
-
Publication number: 20090246197Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.Type: ApplicationFiled: March 23, 2009Publication date: October 1, 2009Inventors: CHARLES DUMONTET, THOMAS FRIESS, FRANK HERTING, CHRISTIAN KLEIN, PABLO UMANA
-
Publication number: 20090182058Abstract: The present invention relates to novel chalcone derivatives of formula (I): wherein X, Y, Z, W, RI, R2, R3, R4 and R5 are as defined, said derivatives having antimitotic activity, as well as to pharmaceutical compositions containing such compounds and to their use for making drugs.Type: ApplicationFiled: January 15, 2007Publication date: July 16, 2009Inventors: Ahcene Boumendjel, Charles Dumontet, Madeleine Blanc, Anne-Marie Mariotte